Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies.
The Biden administration recognises the difficulties in obtaining medical care and medicines for the American population, especially in the current economic climate and the increased cost of drugs.
“We know that prices are still too high for too many things, that times are still too tough for too many families,” Biden stated. “But we’ve made progress."
With the measures introduced with the Inflation Reduction Act and the price capping negotiations, efforts have been made by the US government to improve the situation for patients, and this latest ruling hopes to enable further access to medicine and medical supplies.
This measure, the Defence Production Act, should help to combat issues from disrupted supply chains and drug price increases. The administration includes this act in an announcement of 30 measures designed to increase access to medicine.
The act, backed by President Biden authorises the Department of Health and Human Services to use powers to enable investments in essential medicines. The White House also stated that areas of investment also include "medical countermeasures," encompassing supplies that diagnose, prevent, and treat diseases related to chemical, biological, radiological, or nuclear attacks or incidents.
There are also plans in place to improve the traceability and monitoring of pharmaceutical and industrial supply chains, to measure data, predict, and counter any disruptions that may occur, leading to problems further down the value chain that ultimately impacts patients. One such advancement from the Commerce Department is the development of novel tools and technology to assess potential risks to the supply chain, which they plan to use in conjunction with the Energy Department to monitor the renewable energy resource supply chain.
As the presidential campaigns are gearing up for the next election, polling surveys show that inflation and the economic climate are considered a high concern for the US population, and something for the candidates and parties to consider ahead of the election.
Supply chains have recovered markedly since the COVID-19 pandemic and from politically-driven disruptions, but there is still much work to be done to increase the security and reliability of supply chains and ensure that medical supplies can be accessed by the people in need.
Source: Reuters. Biden invokes Cold War-era measure to boost medical supplies. [Date Accessed 28/11/2023] www.reuters.com/world/us/biden-invoke-cold-war-era-law-boost-medical-supplies-2023-11-27/
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance